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Abstract
Background: We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors
(1 year) compared with women with no history of cancer.
Methods: Studies were identified by searching MEDLINE, PsycINFO, the Cumulative Index to Nursing and Allied Health
Literature, and the Social Sciences Citation Index, and through backward citation tracking. Two researchers selected the
studies, extracted data, and assessed the risk of bias.
Results: Sixty studies were included. Of 38 studies of depression, 33 observed more depression in breast cancer survivors; this
was statistically significant in 19 studies overall, including six of seven where depression was ascertained clinically, three of
four studies of antidepressants, and 13 of 31 that quantified depressive symptoms. Of 21 studies of anxiety, 17 observed more
anxiety in breast cancer survivors, statistically significant in 11 studies overall, including two of four with clinical/
prescription-based outcomes, and in eight of 17 of anxiety symptoms. Breast cancer survivors also had statistically signifi-
cantly increased symptoms/frequency of neurocognitive dysfunction (18 of 24 studies), sexual dysfunctions (5 of 6 studies),
sleep disturbance (5 of 5 studies), stress-related disorders/PTSD (2 of 3 studies), suicide (2 of 2 studies), somatisation (2 of 2
studies), and bipolar and obsessive-compulsive disorders (1 of 1 study each). Studies were heterogeneous in terms of partici-
pants’ characteristics, time since diagnosis, ascertainment of outcomes, and measures reported. Approximately one-half of
the studies were at high risk of selection bias and confounding by socio-economic status.
Conclusions: There is compelling evidence of an increased risk of anxiety, depression and suicide, and neurocognitive and
sexual dysfunctions in breast cancer survivors compared with women with no prior cancer. This information can be used to
support evidence-based prevention and management strategies. Further population-based and longitudinal research would
help to better characterize these associations.
Women with a history of breast cancer are the largest group of
cancer survivors in high-income countries (1). In the United
States alone, more than 2.9 million women were estimated in
2012 to be living with a previous diagnosis of breast cancer (2).
By 2022, this number is estimated to approach 4 million (2).
Similarly, in the United Kingdom, the number of women living
beyond breast cancer is expected to surpass 1.5 million during
the next 20 years (3).
A diagnosis of breast cancer is often overwhelmingly dis-
tressing (4). Women frequently experience some combination
of anger, anxiety, despair, helplessness, fear of death, and sui-
cidal thoughts (5,6). Clinically relevant symptoms of anxiety
and/or depression are common during the treatment period
(7,8), when acute treatment side effects may restrict daily activi-
ties (9). High prevalence of depressive symptoms and anxiety
have also been observed during survivorship (10,11), with one
study finding depressive symptoms persisting for at least two
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years after diagnosis in one in five women (12). Other adverse
mental health outcomes, such as sleep disturbance, have also
been reported both during cancer treatment and afterwards
(13). A substantial proportion of the breast cancer survivors ex-
perience long-term iatrogenic effects of treatment, including fa-
tigue, persistent pain, lymphedema, vasomotor symptoms, and
infertility, all of which may negatively affect quality of life and
mental health (14). Other important psychological challenges in
the long term can include difficulties in re-adapting to profes-
sional, social, and intimate relationships and coping with the
uncertainty about the future (15).
To our knowledge, no systematic review to date has summa-
rized the evidence from studies comparing breast cancer survi-
vors with a noncancer control group for a broad spectrum of
adverse mental health outcomes. Therefore, the aim of this
study was to identify and summarize the studies that have
quantitatively compared mental health outcomes in breast can-
cer survivors (1 year) vs women who did not have cancer; we
also assessed the quality of the evidence on this topic by apply-
ing objective quality assessment criteria.
Methods
This review was registered in the International Prospective
Register of Systematic Reviews (PROSPERO 2017:
CRD42017056946) and followed the a priori methods outlined in
the protocol (published elsewhere [16]). Results were reported in
accordance with the guidance of the Preferred Reporting Items
for Systematic review and Meta-Analysis (17).
Outcomes
The predefined outcomes of interest were anxiety disorders; bi-
polar and related disorders; disruptive, impulse control, and con-
duct disorders; feeding and eating disorders; mood disorders;
neurocognitive disorders; neurotic disorders; personality disor-
ders; schizophrenia spectrum and other psychotic disorders;
sexual dysfunctions of psychological nature; sleep wake disor-
ders; somatoform disorders; substance-related disorders (includ-
ing alcoholism); and trauma- and stressor-related disorders. We
also considered eligible the studies providing data on self-
injurious behavior (including self-harm, suicide, and suicidal
ideation). These categories were selected after systematically
reviewing those listed in the Diagnostic and Statistical Manual
of Mental Disorders, 5th edition (18) and in the ICD-10
Classification of Mental and Behavioural Disorder (19) to exclude
conditions with usual onset during childhood or with strong ge-
netic component (eg Huntington’s disease). The comprehensive
list of outcomes was aimed at exploring what evidence was
available on the topic without making strong assumptions as to
whether the stress induced by the breast cancer diagnosis and
treatment could trigger the condition. The outcomes of interest
were disorders clinically diagnosed, but we also considered
symptomatology evaluated with psychometric instruments.
Data Sources and Identification
Potentially eligible studies were identified in four databases:
MEDLINE, PsycINFO, the Cumulative Index to Nursing and
Allied Health Literature, and the Social Sciences Citation Index.
A search expression tailored for each database was created in-
cluding terms for the exposure (breast cancer), outcomes (the
predefined mental disorders), and comparators (eg, risk) (full
MEDLINE search string provided in the Appendix [Supplementary
Table 1, available online]). Results retrieved from the inception of
the databases up to November 1, 2017 were considered for this
study. Two authors screened the list of references by applying
the same inclusion and exclusion criteria to determine each
study’s eligibility. The bibliographic references of eligible studies
were manually screened to detect additional studies.
Study Eligibility
We considered as eligible observational studies that provided
original data comparing the prevalence, incidence, or odds/haz-
ard of at least one of the predefined lists of mental health out-
comes (see above), clinically diagnosed or their
symptomatology assessed through validated instruments, be-
tween adult female breast cancer survivors and a comparison
group of women with no prior cancer. Female breast cancer sur-
vivors were defined as women with a history of breast cancer or
in situ tumor for one year or longer. Studies with patients diag-
nosed with breast carcinomas in situ were included because de-
spite of their excellent prognosis (20), they receive similar
treatment to invasive breast cancers (21), and patients often ex-
perience substantial psychological distress both during and af-
ter the treatment period (22,23). Studies with no control group
but reporting standardized incidence ratios were also eligible if
the standardization was against a general female population.
Studies that used psychometric instruments that had been al-
tered from the standard/validated version were excluded, ex-
cept where the alteration was limited to omission of questions
that would not apply to the population under study. Studies in-
cluding women who were institutionalized, under active treat-
ment for breast cancer (excluding endocrine therapy), or who
were specifically selected based on distressing psychological
and/or physical symptoms were excluded. Studies evaluating
the effect of further screening or diagnostic tests for cancer on
the mental health of breast cancer survivors were excluded.
There was no restriction in the language of study publication.
The eligibility of individual studies was assessed by two
reviewers (HC and MM, or HC and RH) who independently ap-
plied the predefined inclusion/exclusion criteria. Initial agree-
ment between reviewers in the assessment of abstracts was
92.5% for HC/MM and 81.3% for HC/RH (Cohen’s kappa [j] ¼ 0.51
and 0.32, respectively), and initial agreement in the full-text as-
sessment was 95.9% (j¼ 0.69) and 90.6% (j¼ 0.54), respectively.
All discordant assessments were discussed and successfully
resolved.
Data Extraction
We systematically abstracted data on the characteristics of the
study and study samples. We extracted quantitative data on the
frequency (incidence or prevalence) or severity (mean scores) of
adverse mental health outcomes for each participant’s group or
for the comparison between groups (eg, relative risk, hazard ra-
tio, odds ratio), as available, and the results of any hypothesis
testing reported in the original studies. Prevalences from stud-
ies involving psychometric instruments were based on the cut-
offs defined by the authors of the original studies. When two or
more studies reported data on the same study population, we
extracted data from the study with largest sample size, or if
equal, the one providing more detailed outcome information.
Data were extracted independently by two investigators (HC
and MM, or HC and RH) and discrepancies were resolved.
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Risk of Bias in Individual Studies
The risk of bias in the included studies was assessed by two
reviewers who independently evaluated domains previously
identified as important in observational studies (24). The
domains were: participants’ selection, outcome assessment,
temporality (breast cancer diagnosed prior to the onset of the
mental health outcome), control for confounding by age and
socio-economic status, statistical methods, handling of missing
data, and disclosure of conflicts of interest. Within each do-
main, the studies were rated as having a high, low, or unclear
risk of bias; some criteria were not applicable to all studies.
Supplementary Table 2 (available online) provides the criteria
used for each category and domain.
Statistical Methods
Tables, graphs, and descriptive text were used to summarize
study characteristics and results stratified by mental health out-
come and method used to define outcomes (ie, clinical diagnosis,
drug prescription, or symptoms). When sufficient information
was provided in the original studies, we calculated the preva-
lence ratio for each outcome (25) if this was not directly reported
in the paper. If prevalence data were provided by severity catego-
ries, we computed prevalence ratios for the comparison of mild
to severe symptoms of the outcome between the two groups;
this was the most common dichotomization in the studies that
did not provide results by severity. The 95% confidence intervals
(CIs) for derived prevalence ratios were estimated using the delta
method (25). P values for the comparison of mean scores from
psychometric instruments between breast cancer survivors and
women who did not have cancer were estimated with the inde-
pendent samples t test; all tests were two-sided. To ensure com-
parability of the results across studies, we applied a type-1 error
rate (a) of .05 when summarizing statistical significance even if
studies themselves had provided results using a different statis-
tical significance level. A quantitative synthesis of the results (ie,
meta-analysis), as planned in the study protocol (16), was not
possible due to the heterogeneity of the eligible studies in the
clinical characteristics of the cancer survivors, time elapsed
since breast cancer diagnosis, and instruments used to evaluate
symptoms of mental health disorders.
Results
Characteristics of Included Studies
Of the 7517 individual publications identified, 729 studies were
eligible for full-text evaluation, and 60 (26–85) were ultimately
included (Figure 1). The most commonly evaluated outcomes
were anxiety (n¼ 21 studies), depression (n¼ 38), neurocogni-
tive dysfunction (n¼ 24), and sexual dysfunction (n¼ 6)
(Table 1). Schairer et al. (41) estimated the risk of suicide in
more than 720 000 women diagnosed with breast cancer in 1953
to 2001, using data from 16 population-based cancer registries
in Scandinavia and the United States; thus, only two studies
were eligible for suicide, because smaller studies with overlap-
ping data were excluded. The studies were heterogeneous in
study design, participants’ characteristics, and methods in-
volved to assess outcomes. A total 38 of 60 studies (63.3%) in-
cluded small, nonprobabilistic samples of breast cancer
survivors. Mental health outcomes were most commonly evalu-
ated with psychometric instruments (50/60 studies¼ 83.3%),
followed by clinical diagnoses registered in electronic health-
care databases (10/60¼ 16.7%).
Findings for Specific Mental Health Outcomes
Table 2 provides an overview of the directions of association
reported for all studies/outcomes and statistical significance of
the between-group comparisons. Figure 2 summarizes the rela-
tive measures of effect for the most commonly studied out-
comes in the studies where these were available. Figure 3
shows the prevalence (for cross-sectional analyses) or cumula-
tive incidence (for follow-up analyses) of outcomes in the sam-
ples of breast cancer survivors included in the original studies.
Anxiety
Twenty-one eligible studies reported data for anxiety (Table 1;
Supplementary Table 3, available online). Of 21 studies, 17
(81.0%) observed increased anxiety in the breast cancer survivor
group compared with the noncancer group; the difference was
statistically significant in 11 of 21 (52.4%) studies (Table 2).
Four longitudinal, population-based studies evaluated anxi-
ety with clinical diagnoses (n¼ 2) or clinical diagnoses and anx-
iolytics prescription (n¼ 2); all used electronic health records
data and pointed towards an increased risk in breast cancer sur-
vivors, but this was supported by strong statistical evidence in
two studies only (Figure 2). The relative risk estimates in the
four studies of clinically assessed anxiety varied between 1.06
(95% CI ¼ 0.97 to 1.16) and 2.00 (95% CI ¼ 1.69 to 2.37). The two
studies that reported on anxiolytics prescription reported an 8%
(95% CI ¼ 1% to 15%) and 47% (95% CI ¼ 35% to 61%) increase in
breast cancer survivors compared with women who did not
have cancer (Figure 2).
Seventeen studies investigated symptoms of anxiety us-
ing scales (Table 2). There was strong statistical evidence of
increased symptoms of anxiety in eight of 17 studies, includ-
ing in the six of 12 studies that focused on comparing mean
scores between groups, and in two of five studies that
reported prevalence of scoring above a clinically relevant
threshold. For all of the latter, observed prevalence was
higher in cancer survivors but confidence intervals were gen-
erally wide (Figure 2).
Prevalences of anxiety were generally less than 20% when
electronic health records or anxiolytics were studied and in the
range of 20% to 50% when scales were used (Figure 3).
Determinants of clinically assessed anxiety were provided in
one study. Clinically diagnosed anxiety in breast cancer survi-
vors tended to decrease over time since diagnosis (58) and was
independently associated with younger age and presence of
comorbidities at diagnosis, having less favorable tumor charac-
teristics, and receiving chemotherapy (58).
Depression and Suicide
Thirty-eight studies provided data on depression (Table 1;
Supplementary Table 4, available online), and 33 of 38 (86.8%)
described more depression in the breast cancer survivor group
compared with women who did not have cancer, with 19 fo 38
(50.0%) reporting statistical evidence of increased depression
(Table 2).
Of seven studies that analyzed depression based on clinical
diagnoses, six found strong evidence of an elevated risk among
breast cancer survivors, with relative risk estimates ranging
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from 1.06 (95% CI ¼ 1.00 to 1.12) to 2.04 (95% CI ¼ 1.76 to 2.36)
(Figure 2). All four studies defining depression by antidepres-
sant use found higher use in breast cancer survivors, though for
one smaller study the confidence interval was wide and over-
lapped the null; relative risk estimates ranged between 1.16
(95% CI ¼ 1.11 to 1.22) and 2.06 (95% CI ¼ 1.94 to 2.18).
Of 31 studies that evaluated depressive symptoms with
scales, 13 reported strong statistical evidence of higher severity
of depressive symptoms among women who had breast cancer
(Table 2); among these, eight of nine studies that focused on the
prevalence of scoring above a clinically relevant threshold
found higher prevalence in breast cancer survivors, but this was
No. of studies Adverse mental health outcome 
21 Anxiety 
1 Bipolar disorder 
38 Depression 
24 Neurocognitive dysfunction 
1 Obsessive compulsion 
3 Post-traumatic stress 
6 Sexual dysfunction 
5 Sleep disturbances 
2 Somatization 
2 Suicide 
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n 9,392 records identified in MEDLINE, PsycINFO, CINAHL and SSCI 
669 articles excluded: 
  62  review articles, comments, editorials or conference abstracts 
  90  studies with no data for an adverse mental health outcome
        measured with a validated instrument or clinical diagnosis 
349  studies did not provide data for a female population based
        comparison group 
  26  studies in which the selection of the participants 
        depended on a mental health outcome 
  98  studies including patients undergoing the core treatment 
        for breast cancer or patients diagnosed with breast cancer 
        less than 1 year prior, or at unknown time 
    43  studies providing data that were not possible to be extracted 
    1  study provided data for the same sample as another study
60 studies eligible for the systematic review 
7,517 records screened (title and abstract)
Sc
re
en
in
g
1,875 duplicate records excluded 
729 full-text articles screened for eligibility
6,809 records excluded: 
1,530  review articles, comments, editorials, conference 
           abstracts, case reports and studies involving animals 
   727  studies not including adult women who had a diagnosis of 
           breast cancer 
2,410  studies did not provide data for an adverse mental health 
           outcome in women who had breast cancer 
   374  studies including patients undergoing the treatment 
           for breast cancer or who were institutionalised 
1,538  studies did not provide data for a female comparison 
           group without breast cancer 
   230  studies in which the selection of the participants 
           depended on a mental health outcome
21 studies 
identified from the 
list of references 
Figure 1. Systematic review flowchart. CINAHL¼Cumulative Index to Nursing and Allied Health Literature; SSCI¼Social Sciences Citation Index.
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statistically significant in only three studies and most estimates
again had wide confidence intervals (Figure 2).
The prevalence of depression in breast cancer survivors was
highest when evaluated with self-reported instruments (with
most estimates >30%) and lower for clinically diagnosed de-
pression (most estimates <10%; Figure 3). Determinants of de-
pression clinically assessed in breast cancer survivors were
seldom reported. Independent predictors of clinically diagnosed
depression included younger age, having comorbidities at diag-
nosis and less favorable tumor characteristics (42,58), living
alone, and having lower levels of education (42).
Two studies of suicide found breast cancer survivors to have
37% (95% CI ¼ 28% to 47%) to 60% (95% CI ¼ 21% and 112%)
higher risk than women in the comparison group (Figure 2).
Neurocognitive Dysfunction
Twenty-four studies evaluated domains of neurocognitive func-
tion (Table 1; Supplementary Table 5, available online). All stud-
ies described that breast cancer survivors performed worse
than noncancer controls for one or more domains of neurocog-
nitive function (Table 2); this was supported by strong statistical
evidence in 18 of 24 (75.0%) studies. When prevalence estimates
were provided, all seven studies showed point estimates tend-
ing towards an increased neurocognitive dysfunction in breast
cancer survivors compared with control subjects, even though
this was supported by strong statistical evidence in only three
instances; prevalence ratio estimates varied between 1.54 (95%
CI ¼ 0.95 to 2.49) and 5.51 (95% CI ¼ 1.86 to 16.30) (Figure 2).
Of the 24 studies of neurocognitive dysfunction, 21 investi-
gated the effect of being exposed to chemotherapy vs no che-
motherapy; these studies consistently showed increased risk of
neurocognitive impairments in breast cancer survivors exposed
to chemotherapy. Three studies evaluated the effect of being
exposed to hormone therapy in chemotherapy-naı¨ve patients
(29,82,85); two found strong evidence of increased neurocogni-
tive dysfunction among breast cancer survivors exposed to hor-
mone therapy. In most studies, neurocognitive impairments
were described to affect 20% to 40% of women one year post-
diagnosis (Figure 3).
Table 1. Summary of the main characteristics of the eligible studies
(N¼ 60)
Study characteristic
Studies,
n (%)
Type of study
Cohort 22 (36.7)
Cross-sectional 38 (63.3)
Type of population
Population-based 10 (16.7)
Convenience samples recruited at health institutions 43 (71.7)
Randomly selected 3 (5.0)
Convenience samples recruited from the community 7 (11.7)
Randomly selected 0 (0.0)
Characteristics of the women with history of breast cancer
Mean/median age
49 y 16 (26.7)
50–69 y 41 (68.3)
70 y 3 (5.0)
Mean/median time since diagnosis*
1 y 12 (20.0)
>1 and 5 y 26 (43.3)
>5 and 10 y 17 (28.3)
>10 y 5 (8.3)
Sample size†
<50 18 (30.0)
50–100 20 (33.3)
101–1000 14 (23.3)
>1000 8 (13.3)
Stage at diagnosis inclusion criteria
In situ only 1 (1.7)
In situ and nonmetastatic invasive 6 (10.0)
In situ and invasive all stages 3 (5.0)
Invasive, nonmetastatic 30 (50.0)
Invasive, all stages 20 (33.3)
Treatment-related inclusion criteria
Breast-conserving surgery 1 (1.7)
Mastectomy 5 (8.3)
Breast reconstruction 2 (3.3)
Chemotherapy 13 (21.7)
No chemotherapy 1 (1.7)
Hormone therapy 3 (5.0)
Radiotherapy 2 (3.3)
Immunotherapy 0 (0.0)
All treatments 33 (55.0)
Disease progression related inclusion criteria
Only patients who did not have recurrence or relapse 15 (25.0)
Only patients who were tumor free at recruitment 12 (20.0)
Patients with disease recurrence included‡ 19 (31.7)
Unclear 14 (23.3)
Adverse mental health outcome§
Anxiety 21 (35.0)
Bipolar disorder 1 (1.7)
Depression 38 (63.3)
Neurocognitive dysfunction 24 (40.0)
Obsessive compulsion 1 (1.7)
Sexual dysfunction 6 (10.0)
Sleep disturbances 5 (8.3)
Stress-related / posttraumatic stress 3 (5.0)
Somatization 2 (3.3)
Suicide 2 (3.3)
(continued)
Table 1. (continued)
Study characteristic
Studies,
n (%)
Adverse mental health outcome assessment§
Clinical diagnosis 10 (16.7)
Pharmacological treatmentk 5 (8.3)
Psychometric instruments 50 (83.3)
*Or mean/median time since treatment completion, as reported in the original
studies.
†Refers to patients included in analysis.
‡Includes studies that explicitly stated the inclusion of patients with recurrence,
and longitudinal studies including newly diagnosed patients and that did not re-
port exclusions related to recurrence/relapse during follow-up.
§Studies may have provided data for more than one outcome and may have
assessed one outcome by more than one method.
kIncludes self-reported medication intake.
R
EV
IE
W
H. Carreira et al. | 5
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
T
ab
le
2.
Su
m
m
ar
y
o
f
th
e
re
su
lt
s
o
f
th
e
st
u
d
ie
s
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
an
d
st
u
d
ie
s’
q
u
al
it
y
as
se
ss
m
en
t*
St
u
d
y
Sa
m
p
le
si
ze
(B
C
S/
co
n
tr
o
ls
)
A
n
xi
et
y
B
ip
o
la
r
D
ep
re
ss
io
n
N
eu
ro
-
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
†
O
bs
es
si
ve
co
m
p
u
ls
io
n
Se
xu
al
d
ys
fu
n
ct
io
n
†
Sl
ee
p
d
is
tu
rb
an
ce
†
So
m
at
iz
at
io
n
St
re
ss
-
re
la
te
d
d
is
o
rd
er
s
/P
T
SD
Su
ic
id
e
St
u
d
ie
s
ri
sk
o
f
bi
as
as
se
ss
m
en
t‡
D
ia
g
D
ru
g
Sy
m
p
D
ia
g
D
ru
g
Sy
m
p
Se
l
In
f
T
em
p
C
o
n
f
St
at
M
is
s
C
O
I
A
er
ts
,2
01
4
(4
5)
11
4/
14
9
—
—
—
—
—
—
H
§
—
—
—
—
—
—
—
Y
?
Y
Y
N
?
N
A
h
le
s,
20
10
(7
7)
11
0/
39
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
Y
N
N
N
N
?
N
A
m
ir
,2
00
2
(2
6)
39
/3
9
—
—
H
§
—
—
—
H
§
—
H
§
—
—
H
§
—
—
?
?
Y
N
N
?
Y
A
n
co
li
-I
sr
ae
l,
20
14
(2
7)
44
/3
5
—
—
—
—
—
—
H
§
—
—
—
H
§
—
—
—
?
?
N
N
N
?
N
B
ai
le
y,
20
10
(4
6)
51
5/
49
6
—
—
—
—
—
—
L
—
—
—
—
—
—
—
?
?
Y
Y
N
?
N
B
iz
et
ti
Pe
la
i,
20
12
(6
0)
89
/4
3
—
—
—
—
—
—
H
—
—
—
—
—
—
—
?
?
Y
Y
—
?
Y
B
o
eh
m
er
,
20
15
(2
8)
85
/8
5
—
H
H
—
—
H
H
—
—
—
—
—
—
—
Y
?k
/Y
¶
Y
Y
N
?
N
B
o
eh
m
er
,
20
14
(4
7)
85
/8
5
—
—
—
—
—
—
—
—
—
H
§
—
—
—
—
Y
?
Y
Y
N
?
N
B
o
el
e,
20
15
(2
9)
63
/4
4
—
—
H
—
—
—
H
H
§
—
—
—
—
—
—
Y
?
N
N
N
?
N
B
re
zd
en
,2
00
0
(7
0)
40
/3
6
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
Y
?
Y
N
N
?
Y
B
ro
ec
ke
l,
20
02
(3
0)
58
/6
1
—
—
—
—
—
—
H
§
—
—
H
§
—
—
—
—
Y
?
Y
Y
N
?
Y
C
al
vi
o
,2
01
0
(3
1)
12
2/
11
3
—
—
H
§
—
—
—
H
§
H
§
—
—
—
—
—
—
Y
?
Y
N
N
?
N
C
as
te
ll
o
n
,
20
04
(7
4)
53
/1
9
—
—
L§
,#
—
—
—
L
H
§
—
—
—
—
—
—
Y
?
Y
?
N
?
N
C
la
u
s,
20
06
(4
8)
(i
n
si
tu
)
79
5/
70
2
—
—
—
—
—
—
H
§
—
—
H
§
—
—
—
—
Y
?
Y
N
N
?
N
C
o
h
en
,2
01
1
(3
2)
56
/6
6
—
—
H
§
—
—
—
H
—
—
—
—
H
§
—
—
Y
?
Y
N
N
?
Y
C
o
ll
in
s,
20
14
(6
7)
54
/5
4
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
Y
N
N
N
N
?
N
C
o
n
ro
y,
20
13
(8
3)
24
/2
3
—
—
L
—
—
—
L
H
§
—
—
—
—
—
—
?
?
Y
N
N
?
N
D
ah
l,
20
11
(3
3)
33
7/
16
85
—
—
H
§
—
—
—
L§
—
—
—
H
§
—
—
—
?
?
Y
N
N
?
N
Ea
rl
e,
20
07
(3
4)
46
3/
31
08
—
—
—
—
H
§
—
—
—
—
—
—
—
—
—
N
N
Y
N
—
—
Y
(c
o
n
ti
n
u
ed
)
R
EV
IEW
6 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
T
ab
le
2.
(c
o
n
ti
n
u
ed
)
St
u
d
y
Sa
m
p
le
si
ze
(B
C
S/
co
n
tr
o
ls
)
A
n
xi
et
y
B
ip
o
la
r
D
ep
re
ss
io
n
N
eu
ro
-
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
†
O
bs
es
si
ve
co
m
p
u
ls
io
n
Se
xu
al
d
ys
fu
n
ct
io
n
†
Sl
ee
p
d
is
tu
rb
an
ce
†
So
m
at
iz
at
io
n
St
re
ss
-
re
la
te
d
d
is
o
rd
er
s
/P
T
SD
Su
ic
id
e
St
u
d
ie
s
ri
sk
o
f
bi
as
as
se
ss
m
en
t‡
D
ia
g
D
ru
g
Sy
m
p
D
ia
g
D
ru
g
Sy
m
p
Se
l
In
f
T
em
p
C
o
n
f
St
at
M
is
s
C
O
I
El
R
afi
h
i-
Fe
rr
ei
ra
,
20
11
(6
3)
50
/5
0
—
—
—
—
—
—
—
—
—
—
H
§
—
—
—
?
?
Y
Y
—
?
Y
Er
n
st
,2
00
2
(8
5)
16
/3
3
—
—
—
—
—
—
—
H
—
—
—
—
—
—
Y
?
Y
Y
N
?
N
Fa
n
,2
00
5
(6
8)
91
/8
3
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
?
N
N
N
N
?
N
Fa
n
g,
20
12
(6
4)
74
97
7/
N
D
—
—
—
—
—
—
—
—
—
—
—
—
—
H
§
N
N
N
N
N
—
N
Fr
az
ze
tt
o
,
20
12
(4
9)
(R
)
32
/3
5
—
—
—
—
—
—
H
§,
**
—
—
—
—
—
—
—
?
?
Y
Y
—
?
N
G
ar
ci
a-
T
o
rr
es
,
20
13
(3
5)
22
/2
2
—
—
L
—
—
—
H
—
—
—
—
—
—
—
Y
?
Y
Y
N
?
Y
G
u
re
vi
ch
,
20
04
(5
0)
66
/6
9
—
—
—
—
—
—
—
—
—
—
—
—
H
§
—
Y
?
Y
Y
N
?
Y
H
er
m
el
in
k,
20
17
(5
9)
56
/1
50
—
—
—
—
—
—
H
§
H
††
—
—
—
—
—
—
?
?k
/N
Y
?
N
N
Y
H
je
rl
,2
00
2
(5
1)
60
43
1‡
‡/
N
D
H
—
—
—
H
§
—
—
—
—
—
—
—
—
—
N
N
N
Y
N
—
Y
H
u
n
g,
20
13
(5
2)
26
62
9‡
‡/
26
62
9‡
‡
H
§
—
—
H
§
H
§
—
—
—
—
—
—
—
—
—
N
N
N
Y
N
—
N
In
ag
ak
i,
20
07
(8
4)
10
5/
55
—
—
—
—
—
—
—
H
—
—
—
—
—
—
Y
N
Y
Y
N
?
N
Je
n
ki
n
s,
20
06
(7
5)
12
8/
49
—
—
—
—
—
—
—
H
—
—
—
—
—
—
Y
N
N
N
N
N
N
K
h
an
,2
01
0
(3
6)
16
93
8/
67
64
9
H
H
§
—
—
H
H
§
—
—
—
—
—
—
—
—
N
N
N
N
N
—
N
K
im
,2
01
7
( 6
2)
21
30
/8
52
0
—
—
—
—
H
§
—
—
—
—
—
—
—
—
—
N
N
N
N
—
—
N
K
le
in
,2
01
1
(5
3)
65
2/
11
88
—
—
H
§
—
—
—
—
—
—
—
—
—
—
—
Y
?
Y
N
N
?
N
K
o
p
p
el
m
an
s,
20
12
(7
1)
19
6/
15
09
—
—
—
—
—
—
L§
H
§
—
—
—
—
—
—
N
?
Y
N
N
?
N
K
re
u
ke
ls
,
20
08
(7
2)
63
/6
0
—
—
H
§
—
—
—
H
§
H
§
—
—
—
—
—
—
?
?k
/N
Y
Y
N
?
N
K
es
le
r,
20
13
(8
0)
42
/3
5
—
—
—
—
—
—
H
H
§
—
—
—
—
—
—
Y
?
Y
?
N
?
N
Le
jb
ak
,2
01
0
(8
2)
28
/3
7
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
Y
?
Y
?
N
N
Y
(c
o
n
ti
n
u
ed
)
R
EV
IE
W
H. Carreira et al. | 7
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
T
ab
le
2.
(c
o
n
ti
n
u
ed
)
St
u
d
y
Sa
m
p
le
si
ze
(B
C
S/
co
n
tr
o
ls
)
A
n
xi
et
y
B
ip
o
la
r
D
ep
re
ss
io
n
N
eu
ro
-
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
†
O
bs
es
si
ve
co
m
p
u
ls
io
n
Se
xu
al
d
ys
fu
n
ct
io
n
†
Sl
ee
p
d
is
tu
rb
an
ce
†
So
m
at
iz
at
io
n
St
re
ss
-
re
la
te
d
d
is
o
rd
er
s
/P
T
SD
Su
ic
id
e
St
u
d
ie
s
ri
sk
o
f
bi
as
as
se
ss
m
en
t‡
D
ia
g
D
ru
g
Sy
m
p
D
ia
g
D
ru
g
Sy
m
p
Se
l
In
f
T
em
p
C
o
n
f
St
at
M
is
s
C
O
I
Le
e,
20
11
(6
1)
20
6/
49
6
—
—
—
—
—
—
H
—
—
—
—
—
—
—
N
?
Y
N
N
?
N
M
cD
o
n
al
d
,
20
10
(7
8)
29
/1
8
—
—
H
—
—
—
H
—
—
—
—
—
—
—
?
?
N
Y
N
?
N
M
ia
o
,2
01
6
(7
9)
23
/2
6
—
—
H
—
—
—
H
H
§
—
—
—
—
—
—
?
?
Y
Y
N
?
N
M
in
,2
01
0
(5
4)
52
/1
04
—
—
—
—
—
—
H
§
—
—
—
—
—
—
—
Y
?
Y
Y
—
?
Y
M
ye
rs
,2
01
5
(6
6)
15
6/
46
—
—
—
—
—
—
—
H
§
—
—
—
—
—
—
Y
?
Y
?
N
N
N
N
gu
ye
n
,2
01
3
(8
6)
57
/3
0
—
—
—
—
—
—
H
H
§
—
—
—
—
—
—
Y
?
Y
N
N
?
N
O
tt
e,
20
10
(3
7)
24
6/
24
6
—
—
—
—
—
—
H
§
—
—
—
H
§
—
—
—
Y
?
Y
?
N
?
N
Ph
il
li
p
s,
20
12
(8
1)
12
9/
18
4
—
—
—
—
—
—
—
H
§
—
—
—
—
—
?
N
Y
N
N
?
N
R
o
o
t,
20
15
(6
5)
11
3/
37
—
—
L
—
—
—
H
H
§
—
—
—
—
—
—
?
?
Y
N
N
?
N
R
u
bi
n
o
,2
00
7
(3
8)
33
/3
3
—
—
H
§
—
—
—
H
§
—
—
H
—
—
—
—
?
N
Y
Y
N
?
Y
Sa
fa
ri
n
ej
ad
,
20
13
(3
9)
18
6/
20
4
—
—
—
—
—
—
—
—
—
H
§
—
—
—
—
?
?
Y
N
N
?
N
Sa
le
eb
a,
19
96
(4
0)
52
/8
8
—
—
H
§
—
—
—
—
—
—
—
—
—
—
—
Y
?
Y
N
N
?
Y
Sc
h
ai
re
r,
20
06
(4
1)
72
3
81
0/
N
D
—
—
—
—
—
—
—
—
—
—
—
—
—
H
§
N
N
N
Y
N
—
N
Sc
h
ag
en
,2
00
6
(6
9)
57
/6
0
—
—
—
—
—
—
—
H
—
—
—
—
—
—
Y
N
N
Y
N
?
N
Si
lv
er
m
an
,
20
07
(7
3)
24
/1
0
—
—
—
—
—
—
—
H
—
—
—
—
—
—
?
?
Y
Y
N
?
N
Su
p
p
li
,2
01
4
(4
2)
44
49
4‡
‡/
2M
‡‡
—
—
—
—
H
§
H
§
—
—
—
—
—
—
—
—
N
N
N
Y
N
—
N
V
az
q
u
ez
-
O
rt
iz
,2
01
0
(5
5)
30
/3
0
—
—
—
—
—
—
—
—
—
H
§
—
—
—
—
?
?
Y
Y
N
?
Y
V
o
ig
t,
20
16
(7
6)
15
0/
56
—
—
—
—
—
—
—
—
—
—
—
—
H
§§
—
?
?
N
N
N
N
N
V
o
n
A
h
,2
01
2
(5
7)
62
/7
8
—
—
—
—
—
—
H
—
—
—
H
§
—
—
—
Y
?
Y
N
N
?
N
(c
o
n
ti
n
u
ed
)
R
EV
IEW
8 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
T
ab
le
2.
(c
o
n
ti
n
u
ed
)
St
u
d
y
Sa
m
p
le
si
ze
(B
C
S/
co
n
tr
o
ls
)
A
n
xi
et
y
B
ip
o
la
r
D
ep
re
ss
io
n
N
eu
ro
-
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
†
O
bs
es
si
ve
co
m
p
u
ls
io
n
Se
xu
al
d
ys
fu
n
ct
io
n
†
Sl
ee
p
d
is
tu
rb
an
ce
†
So
m
at
iz
at
io
n
St
re
ss
-
re
la
te
d
d
is
o
rd
er
s
/P
T
SD
Su
ic
id
e
St
u
d
ie
s
ri
sk
o
f
bi
as
as
se
ss
m
en
t‡
D
ia
g
D
ru
g
Sy
m
p
D
ia
g
D
ru
g
Sy
m
p
Se
l
In
f
T
em
p
C
o
n
f
St
at
M
is
s
C
O
I
V
o
n
A
h
,2
00
9
(5
6)
52
/5
2
—
—
—
—
—
—
H
H
§
—
—
—
—
—
—
Y
?
Y
N
N
?
N
W
ei
tz
n
er
,
19
97
(4
3)
60
/9
3
—
—
H
—
—
—
H
§
—
—
—
—
—
—
—
Y
?
Y
N
N
?
Y
Y
an
g,
20
17
(5
8)
(I
n
v)
40
84
9/
45
2
50
7
H
§
H
§
—
—
H
§
H
§
—
—
—
—
—
—
H
§
—
N
N
N
Y
N
—
Y
*W
h
en
a
co
h
o
rt
st
u
d
y
p
ro
vi
d
ed
es
ti
m
at
es
fo
r
m
o
re
th
an
o
n
e
p
o
in
t
in
ti
m
e,
w
e
p
re
se
n
te
d
al
ld
at
a
in
th
e
su
p
p
le
m
en
ta
ry
ta
bl
es
bu
t
d
es
cr
ib
ed
th
e
es
ti
m
at
e
fo
r
o
n
ly
th
e
fi
rs
t
ti
m
e
p
o
in
t
af
te
r
th
e
fi
rs
t
an
n
iv
er
sa
ry
o
f
ca
n
ce
r
d
ia
gn
o
si
s.
W
h
en
a
st
u
d
y
p
ro
vi
d
ed
d
at
a
fo
r
in
va
si
ve
an
d
in
si
tu
tu
m
o
rs
,w
e
p
re
se
n
te
d
th
e
re
su
lt
s
fo
r
th
e
in
va
si
ve
tu
m
o
rs
o
n
ly
.W
h
en
a
st
u
d
y
p
ro
vi
d
ed
d
at
a
o
n
th
e
p
re
va
le
n
ce
o
f
su
bj
ec
ts
co
n
si
d
er
ed
im
p
ai
re
d
as
w
el
l
as
th
e
m
ea
n
sc
o
re
s
o
f
th
e
p
sy
ch
o
m
et
ri
c
in
st
ru
m
en
t,
w
e
sh
o
w
ed
th
e
re
su
lt
o
f
th
e
h
yp
o
th
es
is
te
st
fo
r
th
e
co
m
p
ar
is
o
n
o
f
th
e
p
re
va
le
n
ce
s.
B
C
S
¼
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
;C
O
I¼
co
n
fl
ic
t
o
f
in
te
re
st
;C
o
n
f
¼
co
n
fo
u
n
d
in
g
(b
y
ag
e
an
d
SE
S)
;D
ia
g
¼
cl
in
ic
al
d
ia
gn
o
se
s;
D
ru
g
¼
ba
se
d
o
n
re
l-
ev
an
t
d
ru
g
p
re
sc
ri
p
ti
o
n
s;
H
¼
st
u
d
y
o
bs
er
ve
d
h
ig
h
er
p
re
va
le
n
ce
,r
is
k,
o
r
se
ve
ri
ty
o
f
o
u
tc
o
m
es
in
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
co
m
p
ar
ed
w
it
h
w
o
m
en
w
h
o
d
id
n
o
t
h
av
e
ca
n
ce
r;
In
f
¼
in
fo
rm
at
io
n
bi
as
;I
n
v
¼
in
va
si
ve
tu
m
o
rs
;L
¼
st
u
d
y
o
bs
er
ve
d
lo
w
er
p
re
va
le
n
ce
,r
is
k,
o
r
se
ve
ri
ty
o
f
o
u
tc
o
m
es
in
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
co
m
p
ar
ed
w
it
h
w
o
m
en
w
h
o
d
id
n
o
t
h
av
e
ca
n
ce
r;
M
¼
m
il
li
o
n
;M
is
s
¼
m
is
si
n
g
d
at
a;
N
¼
lo
w
ri
sk
o
f
bi
as
;R
¼
re
cu
rr
en
ce
;S
el
¼
se
le
ct
io
n
bi
as
;S
ta
t
¼
st
at
is
ti
ca
lm
et
h
-
o
d
s;
Sy
m
p
¼
ba
se
d
o
n
sy
m
p
to
m
s;
T
em
p
¼
te
m
p
o
ra
li
ty
o
f
ev
en
ts
;Y
¼
h
ig
h
ri
sk
o
f
bi
as
;?
¼
u
n
cl
ea
r
ri
sk
o
f
bi
as
.
†T
h
e
ri
sk
o
f
n
eu
ro
co
gn
it
iv
e
im
p
ai
rm
en
t,
se
xu
al
d
ys
fu
n
ct
io
n
,a
n
d
sl
ee
p
d
is
tu
rb
an
ce
w
as
co
n
si
d
er
ed
in
cr
ea
se
d
w
h
en
th
e
st
u
d
y
re
p
o
rt
ed
st
at
is
ti
ca
ll
y
si
gn
ifi
ca
n
t
im
p
ai
rm
en
ts
in
o
n
e
o
r
m
o
re
d
o
m
ai
n
s
o
f
n
eu
ro
co
gn
it
iv
e
o
r
se
xu
al
fu
n
ct
io
n
,
o
r
sl
ee
p
,r
es
p
ec
ti
ve
ly
.W
h
en
su
bj
ec
ti
ve
an
d
o
bj
ec
ti
ve
m
ea
su
re
s
o
f
n
eu
ro
co
gn
it
iv
e
fu
n
ct
io
n
w
er
e
p
ro
vi
d
ed
,w
e
co
n
si
d
er
ed
th
e
re
su
lt
s
o
f
th
e
o
bj
ec
ti
ve
m
ea
su
re
s.
‡R
is
k
o
f
bi
as
as
se
ss
m
en
t
w
as
n
o
t
ap
p
li
ca
bl
e
fo
r
th
e
d
o
m
ai
n
o
f
st
at
is
ti
ca
lm
et
h
o
d
s
fo
r
st
u
d
ie
s
w
h
er
e
n
o
re
su
lt
s
fo
r
fo
rm
al
st
at
is
ti
ca
lc
o
m
p
ar
is
o
n
s
be
tw
ee
n
th
e
tw
o
gr
o
u
p
s
w
er
e
p
ro
vi
d
ed
;r
is
k
o
f
bi
as
as
se
ss
m
en
t
w
as
al
so
n
o
t
ap
p
li
ca
bl
e
fo
r
th
e
m
is
si
n
g
d
at
a
d
o
m
ai
n
if
th
e
st
u
d
y
w
as
ba
se
d
o
n
el
ec
tr
o
n
ic
h
ea
lt
h
re
co
rd
s.
§S
ta
ti
st
ic
al
ly
si
gn
ifi
ca
n
t
(P
<
.0
5)
.
kF
o
r
an
xi
et
y
o
r
d
ep
re
ss
io
n
o
u
tc
o
m
es
.
¶
Se
lf
-r
ep
o
rt
ed
an
xi
o
ly
ti
cs
an
d
an
ti
d
ep
re
ss
an
ts
in
ta
ke
.
#B
re
as
t
ca
n
ce
r
su
rv
iv
o
rs
re
p
o
rt
ed
lo
w
er
sy
m
p
to
m
s
fo
r
st
at
e
an
xi
et
y
co
m
p
ar
ed
w
it
h
co
n
tr
o
ls
(P
¼
.0
1)
.N
o
st
at
is
ti
ca
ll
y
si
gn
ifi
ca
n
t
be
tw
ee
n
-g
ro
u
p
d
if
fe
re
n
ce
s
w
er
e
o
bs
er
ve
d
fo
r
tr
ai
t
an
xi
et
y
(P
¼
.0
8)
.
**
Se
ve
re
d
ep
re
ss
io
n
an
d
m
il
d
to
se
ve
re
d
ep
re
ss
io
n
w
er
e
in
cr
ea
se
d
in
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
(P
<
.0
5)
.M
il
d
d
ep
re
ss
io
n
d
id
n
o
t
d
if
fe
r
be
tw
ee
n
gr
o
u
p
s
(P

.0
5)
.
††
T
h
er
e
w
as
n
o
st
ro
n
g
st
at
is
ti
ca
le
vi
d
en
ce
o
f
in
cr
ea
se
d
ri
sk
o
f
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
in
w
o
m
en
w
h
o
h
ad
br
ea
st
ca
n
ce
r
co
m
p
ar
ed
w
it
h
th
e
h
ea
lt
h
y
co
n
tr
o
lg
ro
u
p
.H
o
w
ev
er
,s
tr
o
n
g
st
at
is
ti
ca
le
vi
d
en
ce
fo
r
an
in
cr
ea
se
d
fr
eq
u
en
cy
o
f
co
gn
it
iv
e
d
ys
fu
n
ct
io
n
am
o
n
g
br
ea
st
ca
n
ce
r
p
at
ie
n
ts
w
as
fo
u
n
d
w
h
en
co
n
si
d
er
in
g
th
e
m
ea
n
co
m
p
o
si
te
sc
o
re
s
at
o
n
e
ye
ar
(P
<
.0
5)
;t
h
e
co
m
p
ar
is
o
n
re
m
ai
n
ed
st
at
is
ti
ca
ll
y
si
gn
ifi
ca
n
t
af
te
r
co
rr
ec
ti
n
g
fo
r
m
u
lt
ip
le
te
st
in
g.
‡‡
N
u
m
be
r
o
f
w
o
m
en
at
ba
se
li
n
e;
n
u
m
be
r
o
f
w
o
m
en
at
1
ye
ar
af
te
r
d
ia
gn
o
si
s
n
o
t
re
p
o
rt
ed
.S
u
p
p
li
et
al
:4
4
49
4
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
an
d
1
99
7
66
9
fo
r
d
ep
re
ss
io
n
an
al
ys
is
;t
h
e
co
rr
es
p
o
n
d
in
g
fi
gu
re
s
fo
r
th
e
an
ti
d
ep
re
ss
an
t
an
al
ys
is
w
er
e
35
28
6
(e
xp
o
se
d
to
br
ea
st
ca
n
ce
r)
an
d
1
86
0
55
2
(b
ac
kg
ro
u
n
d
p
o
p
u
la
ti
o
n
).
§§
T
h
er
e
w
as
n
o
st
ro
n
g
st
at
is
ti
ca
le
vi
d
en
ce
o
f
an
in
cr
ea
se
d
ri
sk
o
f
PT
SD
in
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
co
m
p
ar
ed
w
it
h
w
o
m
en
w
it
h
o
u
t
ca
n
ce
r.
H
o
w
ev
er
,t
h
e
m
ea
n
n
u
m
be
r
o
f
PT
SD
sy
m
p
to
m
s
in
br
ea
st
ca
n
ce
r
su
rv
iv
o
rs
w
as
st
at
is
ti
ca
ll
y
si
gn
ifi
-
ca
n
tl
y
h
ig
h
er
fr
o
m
th
e
m
ea
n
n
u
m
be
r
o
f
sy
m
p
to
m
s
in
th
e
co
n
tr
ol
gr
o
u
p
(P
<
.0
01
).
R
EV
IE
W
H. Carreira et al. | 9
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
Sexual Dysfunction
Six studies, all involving convenience samples, reported data
for sexual dysfunction (Table 1). Five of these reported impair-
ments in one or more domains of sexual function (Table 2). All
studies for which prevalence ratios were available showed in-
creased dysfunction in breast cancer survivors, with relative
risk estimates between 1.25 (95% CI ¼ 1.05 to 1.49) and 2.03 (95%
CI ¼ 0.56 to 7.42) (Figure 2), but the width of the confidence
intervals did not exclude the probability of this being due to
Anxiety, clinical diagnosis
Khan et al. 2010 (36)
Hung et al. 2013 (52)
Hjerl et al. 2002 (51)*
Yang et al. 2017 (58) (invasive)
Anxiety, drug treatment
Khan et al. 2010 (36)
Yang et al. 2017 (58) (invasive)
Boehmer et al. 2015 (28) (self-reported)
Anxiety, scale
Boehmer et al. 2015 (28) (HADS≥8)
McDonald et al. 2010 (78) (STAI-T≥65)
Rubino et al. 2007 (38) (HRS-A≥15)†
Saleeba et al. 1996 (40) (STAI-S>85%)
Weitzner et al. 1997 (43) (STAI-T>1SD)
Depression, clinical diagnosis
Khan et al. 2010 (36)
Earle et al. 2007 (34)
Kim et al. 2017 (62)
Hung et al. 2013 (52)
Suppli et al. 2014 (42)
Hjerl et al. 2002 (51)*
Yang et al. 2017 (58) (invasive)
Depression, drug treatment
Suppli et al. 2014 (42)
Khan et al. 2010 (36)
Yang et al. 2017 (58) (invasive)
Boehmer et al. 2015 (28) (self-reported)
Depression, scale
Bailey et al. 2010 (46) (CESD≥16)
Bizetti Pelai et al. 2012 (60) (BDI≥10)
Boehmer et al. 2015 (28) (HADS≥8)
Frazzetto et al. 2012 (49) (GDS≥10)‡
Garcia Torres et al. 2013 (35) (BDI-II≥14)
Lee et al. 2011 (61) (SDS≥50)
McDonald et al. 2010 (78) (CESD≥16)
Rubino et al. 2007 (38) (HRS-D≥8)†
Weitzner et al. 1997 (43) (BDI>12)
Neurocognitive dysfunction
Schagen et al. 2006 (69)
Brezden et al. 2000 (70)
Collins et al. 2014 (67)
Fan et al. 2005 (68)
Jenkins et al. 2006 (75)
Hermelink et al. 2017 (59)
Kreukels et al. 2008 (72)
Sexual dysfunction
Rubino et al. 2007 (38)†
Boehmer et al. 2014 (47)
Claus et al. 2006 (48) (in situ)
Safarinejad et al. 2013 (39)
Suicide
Fang et al. 2012 (64)
Schairer et al. 2006 (41)
ID
Study
≥5 y
~2 y
~1.5 y
~1.5 y
≥5 y
~1.5 y
~4.5 y
~4.5 y
~1.5 y
≥1 y
~8.5 y
~8.5 y
≥5 y
≥5 y
~1 y
~2 y
~1.5 y
~1.5 y
~1.5 y
~1.5 y
≥5 y
~1.5 y
~4.5 y
~1 y
~3.7 y
~4.5 y
≥10 y
~8.2 y
~1 y
~1.5 y
≥1 y
~8.5 y
~1 y
~1 y
~1 y
~1 y
~1 y
~1 y
~1 y
≥1 y
~4.5 y
~5.8 y
~2.4 y
>1 y
~8.7 y
diagnosis
Time since
1.06 (0.97 to 1.16)
1.22 (1.16 to 1.29)
1.40 (0.93 to 2.11)
2.00 (1.69 to 2.37)
1.08 (1.01 to 1.15)
1.47 (1.35 to 1.61)
2.92 (0.31 to 27.09)
1.24 (0.86 to 1.78)
1.25 (0.12 to 12.65)
7.99 (1.06 to 60.34)
3.00 (1.19 to 7.57)
1.80 (0.95 to 3.41)
1.06 (1.00 to 1.12)
1.24 (1.03 to 1.50)
1.55 (1.24 to 1.94)
2.00 (1.80 to 2.22)
1.48 (1.19 to 1.84)
1.87 (1.49 to 2.35)
2.04 (1.76 to 2.36)
2.06 (1.94 to 2.18)
1.16 (1.11 to 1.22)
1.92 (1.76 to 2.09)
1.61 (0.97 to 2.67)
0.90 (0.80 to 1.02)
1.49 (0.97 to 2.28)
1.19 (0.56 to 2.50)
2.91 (1.69 to 5.03)
2.22 (0.79 to 6.21)
1.06 (0.89 to 1.25)
2.46 (0.30 to 20.20)
3.76 (1.39 to 10.14)
1.93 (1.03 to 3.61)
2.10 (0.51 to 8.61)
4.55 (1.71 to 12.10)
3.67 (1.21 to 11.12)
1.54 (0.95 to 2.49)
1.58 (0.64 to 3.90)
2.43 (0.89 to 6.64)
5.51 (1.86 to 16.30)
2.03 (0.56 to 7.42)
1.44 (0.72 to 2.89)
1.25 (1.05 to 1.49)
1.83 (1.42 to 2.36)
1.60 (1.21 to 2.12)
1.37 (1.28 to 1.47)
PR/OR/RR (95% CI)
OR
RR
SIR
SIR
OR
SIR
PR
PR
PR
PR
PR
PR
OR
PR
PR
RR
RR
SIR
SIR
RR
OR
SIR
PR
PR
PR
PR
PR
PR
PR
PR
PR
PR
OR
PR
PR
PR
PR
RR
RR
PR
OR
PR
PR
RR
SMR
Measure
.5 1 2 4 8 16
Figure 2. Associations between breast cancer history and anxiety, depression, neurocognitive and sexual dysfunctions, and suicide. We considered that anxiolytics
were being taken to treat anxiety and antidepressants to treat depression. Time since diagnosis refers to the mean/median time elapsed since the breast cancer diag-
nosis or completion of initial course of treatment, as reported in the original studies, for the sample of cancer survivors. When this information was not reported in the
original studies, we presented the lower limit of survivorship time reported in the inclusion criteria of the study. The minimum, mean/median, and maximum follow-
up of longitudinal studies are reported in the Supplementary Appendix (available online). *The original study provided relative risk estimates stratified by area of resi-
dence (urban/rural). The combined estimate presented in the forest plot was computed with inverse-variance-weighted meta-analysis methods using the command
“metan” in Stata v14. BDI(-II) ¼ Beck Depression Inventory(-II); CESD ¼ The Center for Epidemiologic Studies, Depression Scale; GDS ¼ Geriatric Depression Scale; HADS
¼ Hospital Anxiety and Depression Scale; HRS-A ¼ Hamilton Rating Scale for Anxiety; HRS-D ¼ Hamilton Rating Scale for Depression; OR ¼ odds ratio; PR ¼ prevalence
ratio; RR ¼ relative risk; SD ¼ standard deviation; SDS ¼ Self-rating Depression Scale; SIR ¼ standardized incidence ratio; SMR ¼ standardized mortality ratio; STAI-S ¼
State-Trait Anxiety Inventory (state anxiety subscale); STAI-T ¼ State-Trait Anxiety Inventory (trait anxiety subscale). †Women who have had breast reconstruction af-
ter mastectomy. ‡Refers to a group of women who had breast cancer recurrence 10 years after the first diagnosis.
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chance in two studies. The prevalence of reported impaired sex-
ual function overall or for specific domains was generally in the
range of 20% to 60% (Figure 3). Safarinejad et al. (39) reported
that women who had radiotherapy, chemotherapy, and hor-
mone therapy had four to six times higher odds of disorder for
all domains, compared with women who did not have cancer
(39) (Supplementary Table 6, available online).
Other Outcomes: Bipolar Disorder, Obsessive-
Compulsive Problems, Stress-Related and Posttraumatic
Stress, Sleep Disturbance, and Somatization
Other outcomes were infrequently studied, but five of five stud-
ies of sleep disturbance found a statistically significantly higher
prevalence in breast cancer survivors, as did two of three stud-
ies of stress-related disorders, two of two studies of
somatization, and the single studies identified with bipolar dis-
order and obsessive-compulsive outcomes (Table 2).
Quality of the Studies
Approximately 50% of the studies were rated at high risk of se-
lection bias, mostly because of the nonprobabilistic recruitment
of participants (eg, fliers and advertisements [28,31,44,47,56,57])
and the low proportion of women who accepted to participate
in the studies (30,45,50,53,54) (Figure 4). In most studies (>70%),
the risk of information bias was unclear, and the cross-sectional
design precluded the unequivocal assertion that the onset of
the mental disorder was posterior to the breast cancer diagno-
sis. Approximately 40% of studies reported results likely to have
been affected by confounding by age and socio-economic status,
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Figure 3. Absolute frequency of anxiety, depression, and neurocognitive and sexual dysfunctions reported in the original studies for breast cancer survivors. Estimates
for cognitive and sexual dysfunctions refer to the prevalence of women impaired for the condition or specific domains, as reported in the original studies. EHR ¼ elec-
tronic health records. Black triangle ¼ cumulative incidence, diagnoses in EHR; white triangle ¼ cumulative incidence, drug treatment; white diamond ¼ prevalence,
psychometric instruments; black diamond ¼ prevalence, psychiatric interview.
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and strategies to handle missing data were seldom reported.
Individual study ratings are provided in Table 2.
Discussion
Anxiety, depression, neurocognitive dysfunction, sexual dys-
function, and suicide appear to be more common in breast can-
cer survivors compared with noncancer groups. Scarcer data
were available for other adverse mental health outcomes, but
they were also reported as increased among breast cancer survi-
vors. Common limitations of the current available evidence in-
clude use of nonprobabilistic samples, cross-sectional study
designs making temporality of events difficult to assess, lack of
power, and lack of consideration for important confounders
such as socio-economic status.
Strengths of this review include the extensive search of
multiple databases, the duplicated screening of the references
and data extraction, and the systematic evaluation of the
quality of the studies. The restriction to studies involving non-
hospitalized samples and the inclusion of studies with in situ
tumors allowed for a more generalizable characterization of
the long-term burden of mental disorders in women in the
community who have had breast cancer. We aimed to reduce
the potential for information bias in the outcomes by consid-
ering only studies in which outcomes were assessed clinically
or with validated instruments. However, this review also has
limitations. Studies that reported mood assessments as sec-
ondary outcomes may not have been identified in the searches
of electronic publication databases if the mental health out-
come was not mentioned in the title, abstract, keywords, or
indexing terms. This problem should have been minimized by
our use of the four largest and most relevant databases in this
field, supplemented by manual searches of all reference lists
to further reduce the chances of major studies being missed.
The comparability of clinically diagnosed outcomes over time
may be limited by the changes in the diagnostic criteria, espe-
cially in cases such as sexual dysfunction where the criteria
became narrower over time (87). We defined explicit criteria to
evaluate the risk of bias in the studies, but our assessment
may have been affected by the quality of the reporting of the
original studies. We considered that confounding by age and
socio-economic status had been accounted for when the stud-
ies matched participants for these factors, even though we ac-
knowledge that matching per se may not completely remove
the confounding effect (88).
The population-based studies included in this review consis-
tently described more depression and anxiety in breast cancer
survivors compared with the general population when these
outcomes were clinically assessed. The group of breast cancer
patients who receive a psychiatric diagnosis or who contact
clinical services in relation to their mental health are likely to
represent the most severe cases only; these patients are likely
to benefit from medical treatment. Studies using receipt of anti-
depressants and anxiolytics prescriptions to define depression
and anxiety, respectively, are likely to capture the specific group
of patients who were thought to benefit from pharmacological
intervention, which is only a subset of all patients with anxiety
and depression. The indication of these drugs was not explored
in any of the original studies, and misclassification of the out-
come may have occurred because some of these drugs have
other indications and are routinely used to manage vasomotor
symptoms secondary to breast cancer treatments (89,90). In ad-
dition, we cannot rule out that patients with breast cancer
Figure 4. Summary of the risk of bias in the studies included in the systematic review. The risk of bias in statistical methods was considered not applicable when for-
mal statistical comparisons between the two groups were not presented in the original study. Missing data criteria were not applicable for studies involving electronic
health records.
R
EV
IEW
12 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
history may have been more likely to be diagnosed with a men-
tal health outcome due to increased contact with the health
services compared with participants who did not have cancer.
The results from the original studies involving self-
assessment scales, especially to assess symptoms of anxiety
and depression, need to be interpreted with caution. These
were often small, low-powered, cross-sectional studies using
nonprobabilistic samples. Several of the original studies ex-
cluded women with psychiatric conditions and relied on volun-
tary participation. This may have resulted in an
overrepresentation of psychologically healthier women, be-
cause diseased people are less likely to volunteer to participate
in epidemiological studies (91,92); it is unclear if this would be
differential between breast cancer survivors and control groups.
The clinical profile of the patents included in these studies may
also have been more favorable, because 45% of the studies in-
cluded only patients with no recurrence and who were disease
free at recruitment. In addition, misclassification of the out-
come may have occurred, because these scales are screening
tools and not suitable to establish definitive diagnoses. For ex-
ample, the Hospital Anxiety and Depression Scale had only 50%
sensitivity as a screening test for major depressive disorder in
breast cancer survivors compared with the Structured Clinical
Interview for the Diagnostic and Statistical Manual of Mental
Disorders (93). Despite these limitations, scales are widely used
in psychiatric epidemiology and in psycho-oncology research,
and their results in this review are helpful to show the consis-
tency of the results across methods of assessment.
For all methods of outcome definition, selective reporting in
the original studies cannot be ruled out. Information on missing
data was rarely well reported, and there was limited adjustment
for potentially important confounders such as age and socio-
economic status; residual confounding is still likely to be pre-
sent in the studies that adjusted for education only.
Clinically relevant symptoms of anxiety and stress-related/
adjustment disorders are common shortly after diagnosis (94),
which is an expected response to a stressor that may be per-
ceived as life-threatening and considering the uncertainty
about the future that women may feel at this point (95).
Declining trajectories of anxiety suggest that most women
adjust to the diagnosis over time (96), but clinically relevant
symptoms may persist in subgroups of women. Evidence on
long-term trajectories of outcomes is scarce and needs to be fur-
ther explored. Reported determinants of anxiety included youn-
ger age at diagnosis and having comorbidities; this is consistent
with literature reporting that young breast cancer survivors
have specific concerns, for example, fertility issues for women
who want more children or weight gain during and after treat-
ments (10). The increased symptoms of posttraumatic stress is
consistent with a meta-analysis reporting that 10% of breast
cancer survivors have posttraumatic stress disorder (97).
Results for somatic and obsessive-compulsive symptoms must
be interpreted with caution because they come from a small
number of studies.
The increased frequency of depression in breast cancer sur-
vivors is plausible considering that many report unmet needs in
several domains that affect quality of life (98), including impact
on relationships, lifestyle changes induced by the cancer, lack
of psychological support, and difficulties obtaining understand-
able information about the physical long-term effects of the
treatments (99–101). Risk factors for depression in breast cancer
patients appear to be similar to those for the general female
population, including less social support and lower
socio-economic status (46). Suicide almost always occurs
among people suffering from a mental health disorder, most of-
ten depression (102,103). The increased risk of suicide in breast
cancer survivors is likely to be underestimated, because suicide
is often classified under other causes of death, and this may
happen more often in women who have had cancer.
Neurocognitive dysfunction, also known as chemo-fog, has
been linked to the neurotoxic effects of chemotherapy (104).
Other determinants of neurocognitive dysfunction recently pos-
tulated include posttraumatic stress disorder (59) and exposure
to hormone therapy due the effects of estrogen deprivation in
the neuronal structures (82). Impairments for one or more
domains of neurocognitive function (eg, memory [65,83] and
processing speed [77,81]) were often described, but the method-
ological heterogeneity of the studies (105) as well as the chal-
lenge to measure neurocognitive function (106) hamper
comparisons, and it is currently debatable which specific
domains are impaired.
The narrow inclusion/exclusion criteria in some eligible
studies of sexual dysfunction preclude generalizability to the
general population of breast cancer survivors. For example,
Safarinejad et al. (39) excluded women who did not attempt sex-
ual intercourse weekly and Boehmer et al. (47) included only in
lesbian or bisexual women. The aetiology of sexual dysfunction
in women with a history of breast cancer is thought to be multi-
factorial. Vaginal dryness is a common iatrogenic effect of hor-
mone therapy or chemotherapy-induced ovarian failure and
may lead to dyspareunia (14). However, impaired sexual func-
tion, compared with healthy women, has also been reported in
women treated with surgery only (48), indicating that factors
other than the physical ones may be involved. Indeed, the dis-
tress in partnered relationships (107–110), body image concerns
(111,112), depressive feelings (113), younger age at diagnosis
(113), and presence of comorbidities (114) have all been reported
amongst the most important determinants of female sexual
dysfunction.
Mitchell et al. (115) systematically reviewed studies provid-
ing data for depression and anxiety in survivors from several
types of cancer (>2 years since diagnosis) and in healthy sub-
jects. The results indicated that anxiety, but not depression,
may be increased among cancer survivors (115). This conclusion
arose from the meta-analysis of nine studies that provided data
for anxiety and included patients diagnosed with breast, colo-
rectal, prostate, testicular, and cervical cancers or Hodgkin’s
lymphomas as well as patients diagnosed with cancers during
adolescence and young adulthood. It is currently unknown if,
and how, the risk of anxiety and depression varies by cancer
type, and thus we cannot directly compare our results. Other
systematic reviews on the topic assessed the prevalence of anx-
iety and depressive symptoms in cancer survivors (11,116–118),
including studies without a comparison group. Maass et al. (11)
described a higher frequency of depressive symptoms among
breast cancer survivors (>1 year since diagnosis) compared with
normative data found in the literature. The results for cognitive
dysfunction are in accordance with those reported by Jim et al.
(119), who found small but increased cognitive deficits in breast
cancer survivors treated with chemotherapy compared with
noncancer and cancer controls.
Several studies have reported no differences in most
domains of health-related quality of life (HRQoL) between long-
term breast cancer survivors and women in the general popula-
tion (120–122). The interpretation of our results in the context of
the literature for HRQoL is not straightforward, and the appar-
ent difference is likely to be explained by the combination of
several factors, including the differential participation of
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psychologically healthier women in HRQoL surveys and positive
effects of surviving breast cancer. Patients with adverse mental
health outcomes, especially those with the most severe catego-
ries, may be less likely to participate in HRQoL surveys. This
contrasts with the studies in this review that included women
with a clinical diagnosis and/or treated for a mental health dis-
order and were thus likely to capture the most severe cases. In
addition, long-term breast cancer survivors report changes in
several aspects of their lives, but not all of them are negative.
Women in the survivorship period have described feeling im-
proved empathy, closer relationships, and a greater apprecia-
tion for life (123). This phenomenon of heightened well-being
after a stressful event—known as posttraumatic stress
growth—has been described to affect up to 60% of breast cancer
survivors (124). Quality of life reflects how women perceive their
current status, and the occurrence of posttraumatic growth
may offset some of the negative feelings associated with breast
cancer (125). In addition, studies of HRQoL often reported mean
scores of overall and domain-specific measures of HRQoL; sub-
groups that have a different trajectory of symptoms can be hard
to disentangle based on standard analyses.
This study has several implications for clinical practice. It is
important to raise awareness amongst health care professionals
acting at various levels of the health care system of the in-
creased risk of mental health symptoms among breast cancer
survivors, in particular anxiety, depression, and neurocognitive
and sexual dysfunctions. Screening for mental health disorders
in some or all of the breast cancer survivor population may be
warranted. Predictors of distress among breast cancer survivors
include having perceived functioning limitations, fatigue, youn-
ger age, lower socioeconomic status, and psychiatric history,
and modifiable factors such as vasomotor symptoms, pain, less
social support, physical activity, and cigarette smoking (126). As
such, screening for anxiety and depression may be especially
relevant for younger patients, and all those within the first few
years of survivorship, with co-morbidities, living alone, or diag-
nosed with more advanced disease; patients with depression
should be assessed for suicidal ideation. Patients who experi-
enced treatment-induced menopause are likely to benefit from
being asked about their sexual function, because they may
avoid this topic with their clinicians; patients who received che-
motherapy may also benefit from assessment for clinically sig-
nificant cognitive impairments. Psychosocial support and
routine monitoring of patient-reported outcomes during survi-
vorship care are likely to help reduce the burden of these condi-
tions. Differentiated psychological services are becoming the
norm in specialized breast cancer clinics; however, only a frac-
tion of the breast cancer survivors are followed-up in these
settings (127). The holistic approach to the patients’ unmet
needs also requires equipping health care professionals with
evidence-based information on the optimal management
strategies. For example, treatment for sexual dysfunction
may require not only management of anxiety and depressive
symptoms, but also vaginal dryness, which may be under-
treated in women with history of estrogen-receptor positive
breast cancer due to concerns over the effect of hormonal
vaginal treatments (128) and unawareness of the recommen-
dations for lubricants and moisturizers (129). Patients’ edu-
cation on common changes post breast cancer, and the
strategies available to manage these, may help women to
better understand and cope with their disease, increase
patients’ awareness of common symptomatology, and help
to decrease the stigma associated with mental health
disorders.
Our review also identified areas for further research. There
is a pressing need for studies evaluating clinically diagnosed ad-
verse mental health outcomes in samples of women likely to
represent the cohort of survivors in the general population and
with sufficient numbers to allow effects to be detected. Further
research is particularly needed to better characterize the trajec-
tories of mental health outcomes over time, particularly of anxi-
ety, depression, and neurocognitive dysfunction. The long-term
risk of sleep disorders needs clarification, because breast cancer
treatments such as chemotherapy and steroids have been sug-
gested to be associated with impaired sleep (130,131), possibly
due to increased risk of vasomotor symptoms that affect the
sleep quality and quantity (132). Evidence on the long-term ef-
fect of being diagnosed in situ vs invasive tumors and on having
undergone breast reconstructive surgery is scarce despite the
increasing numbers of ductal carcinoma in situ diagnoses and
aesthetics surgeries performed. The role of systemic treatments
other than chemotherapy on neurocognitive function also
needs clarification, including the role of the different types of
hormonal treatments (selective oestrogen receptors modulators
vs aromatase inhibitors). Efforts should be made to employ
standardized definitions of the outcomes, because the heteroge-
neity of diagnostic codes and psychometric instruments ham-
pers comparability of results across studies. Further research is
also needed on the performance of commonly used scales for
anxiety and depression as screening tools for these conditions
in breast cancer survivors. Studies should also consider that the
incidence of mental health disorders after a breast cancer diag-
nosis may vary with age, socio-economic status, time, stage of
disease, recurrence, type of treatment, and sequelae from can-
cer among other factors. The inclusion of a comparison group is
essential to estimate the excess risk of the breast cancer
survivorship.
In conclusion, women with a history of breast cancer appear
to be at higher risk of a wide range of adverse mental health
outcomes up to several years post diagnosis and treatment
compared with women who did not have cancer. The evidence
was particularly compelling for anxiety, depression and neuro-
cognitive and sexual dysfunctions, and suicide, which were
most often studied. However, there is a pressing need for more
population-based research to better characterize the associa-
tion between breast cancer history and mental health. Our
results can be used to inform prevention and management
strategies directed at tackling the burden of adverse mental
health outcomes in breast cancer survivors.
Funding
This work was supported by the Medical Research Council
(MRC) and the Clinical Practice Research Datalink (CPRD) at
the Medicines and Healthcare products Regulatory Agency
(MHRA) (grant no. MR/M016234/1 to HC); the Bangerter
Foundation and the Swiss Academy of Medical Sciences
(grant no. TCR 14/17 to MM); and the Wellcome Trust and
the Royal Society (grant no. 107731/Z/15/Z to KB).
Notes
Department of Non-Communicable Disease Epidemiology,
Faculty of Epidemiology and Population Health, London School
of Hygiene & Tropical Medicine, London, UK (HC); Clinical
Practice Research Datalink (CPRD), Medicines and Healthcare
Products Regulatory Agency, London, UK (RW); Department of
R
EV
IEW
14 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
Emergency Medicine, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland (MM); Institute of Health
Economics and Clinical Epidemiology, University Hospital of
Cologne, Cologne, Germany (MM); Department of Non-
Communicable Disease Epidemiology, Faculty of Epidemiology
and Population Health, London School of Hygiene & Tropical
Medicine, London, UK (RH); Department of Medicine, The Royal
Marsden NHS Foundation Trust, London and Surrey, UK (SS);
Department of Non-Communicable Disease Epidemiology,
Faculty of Epidemiology and Population Health, London School
of Hygiene & Tropical Medicine, London, UK (KB).The funders
had no role in the design of the study; the collection, analysis,
and interpretation of the data; the writing of the manuscript;
and the decision to submit the manuscript for publication.
Conflict of interest: Ms Williams reports that CPRD has finan-
cial relationships with its clients, including the London School
of Hygiene and Tropical Medicine, in relation to providing ac-
cess to research data and services outside the submitted work.
Dr Stanway reports personal fees from Roche, Clinigen, Eli Lilly,
and Novartis not related to this work. Dr Bhaskaran reports
grants from Wellcome Trust, the Royal Society, Medical
Research Council, and British Heart Foundation outside the sub-
mitted work. The other authors in this report have no conflict of
interest to disclose.
Acknowledgments: We thank Dr Maja Niksic and Ms Ruoran
Li for their help in interpreting the papers written in Serbian
and Chinese, respectively.
References
1. Ervik M, Lam F, Ferlay J, et al. Population fact sheets: breast cancer preva-
lence (5 years) very high and high HDI. http://gco.iarc.fr/today/fact-sheets-
cancers?cancer¼15&type¼0&sex¼2. Accessed 1 May 2018.
2. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States:
prevalence across the survivorship trajectory and implications for care.
Cancer Epidemiol Biomarkers Prev. 2013;22(4):561–570.
3. Maddams J, Utley M, Moller H. Projections of cancer prevalence in the
United Kingdom, 2010-2040. Br J Cancer. 2012;107(7):1195–1202.
4. Payne DK, Sullivan MD, Massie MJ. Women’s psychological reactions to
breast cancer. Semin Oncol. 1996;23(1 suppl 2):89–97.
5. Al-Azri M, Al-Awisi H, Al-Moundhri M. Coping with a diagnosis of breast
cancer-literature review and implications for developing countries. Breast J.
2009;15(6):615–622.
6. Schubart JR, Emerich M, Farnan M, et al. Screening for psychological distress
in surgical breast cancer patients. Ann Surg Oncol. 2014;21(10):3348–3353.
7. Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with
early breast cancer: five year observational cohort study. BMJ. 2005;
330(7493):702.
8. Kang JI, Sung NY, Park SJ, et al. The epidemiology of psychiatric disorders
among women with breast cancer in South Korea: analysis of national regis-
try data. Psychooncology. 2014;23(1):35–39.
9. Browall M, Ahlberg K, Karlsson P, et al. Health-related quality of life during
adjuvant treatment for breast cancer among postmenopausal women. Eur J
Oncol Nurs. 2008;12(3):180–189.
10. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility con-
cerns, and behavioral health outcomes in younger breast cancer survivors:
a systematic review. J Natl Cancer Inst. 2012;104(5):386–405.
11. Maass SW, Roorda C, Berendsen AJ, et al. The prevalence of long-term
symptoms of depression and anxiety after breast cancer treatment: a sys-
tematic review. Maturitas. 2015;82(1):100–108.
12. Avis NE, Levine BJ, Case LD, et al. Trajectories of depressive symptoms fol-
lowing breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2015;24(11):
1789–1795.
13. Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and
risk factors for insomnia in the context of breast cancer. Sleep. 2001;24(5):
583–590.
14. Fallowfield L, Jenkins V. Psychosocial/survivorship issues in breast cancer:
are we doing better? J Natl Cancer Inst. 2015;107(1):335.
15. Burg MA, Adorno G, Lopez ED, et al. Current unmet needs of cancer survi-
vors: analysis of open-ended responses to the American Cancer Society
Study of Cancer Survivors II. Cancer. 2015;121(4):623–630.
16. Carreira H, Williams R, Muller M, et al. Adverse mental health outcomes in
breast cancer survivors compared to women who did not have cancer: sys-
tematic review protocol. Syst Rev. 2017;6(1):162.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;
151(4):264–269, W64.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders. 5th ed. Washington, DC: American Pshyciatric Association Press;
2013.
19. World Health Organization. The ICD-10 Classification of Mental and Behavioural
Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health
Organization; 1992.
20. Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for
low-grade ductal carcinoma in situ: a population-based cohort study. JAMA
Surg. 2015;150(8):739–745.
21. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the
breast: a systematic review of incidence, treatment, and outcomes. J Natl
Cancer Inst. 2010;102(3):170–178.
22. Lauzier S, Maunsell E, Levesque P, et al. Psychological distress and physical
health in the year after diagnosis of DCIS or invasive breast cancer. Breast
Cancer Res Treat. 2010;120(3):685–691.
23. Mertz BG, Duriaud HM, Kroman N, et al. Pain, sensory disturbances and psy-
chological distress are common sequelae after treatment of ductal carci-
noma in situ: a cross-sectional study. Acta Oncol. 2017;56(5):724–729.
24. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibil-
ity to bias in observational studies in epidemiology: a systematic review
and annotated bibliography. Int J Epidemiol. 2007;36(3):666–676.
25. Kirkwood BR, Sterne JAC. Essential Medical Statistics. Oxford, UK: Blackwell
Science Ltd; 2003.
26. Amir M, Ramati A. Post-traumatic symptoms, emotional distress and qual-
ity of life in long-term survivors of breast cancer: a preliminary research. J
Anxiety Disord. 2002;16(2):195–206.
27. Ancoli-Israel S, Liu L, Rissling M, et al. Sleep, fatigue, depression, and circa-
dian activity rhythms in women with breast cancer before and after treat-
ment: a 1-year longitudinal study. Support Care Cancer. 2014;22(9):2535–2545.
28. Boehmer U, Ozonoff A, Potter J. Sexual minority women’s health behaviors
and outcomes after breast cancer. LGBT Health. 2015;2(3):221–227.
29. Boele FW, Schilder CM, de Roode ML, et al. Cognitive functioning during
long-term tamoxifen treatment in postmenopausal women with breast
cancer. Menopause. 2015;22(1):17–25.
30. Broeckel JA, Thors CL, Jacobsen PB, et al. Sexual functioning in long-term
breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer
Res Treat. 2002;75(3):241–248.
31. Calvio L, Peugeot M, Bruns GL, et al. Measures of cognitive function and
work in occupationally active breast cancer survivors. J Occup Environ Med.
2010;52(2):219–227.
32. Cohen M, Mabjish AA, Zidan J. Comparison of Arab breast cancer survivors
and healthy controls for spousal relationship, body image, and emotional
distress. Qual Life Res. 2011;20(2):191–198.
33. Dahl AA, Nesvold IL, Reinertsen KV, et al. Arm/shoulder problems and in-
somnia symptoms in breast cancer survivors: cross-sectional, controlled
and longitudinal observations. Sleep Med. 2011;12(6):584–590.
34. Earle CC, Neville BA, Fletcher R. Mental health service utilization among
long-term cancer survivors. J Cancer Surviv. 2007;1(2):156–160.
35. Garcia-Torres F, Alos FJ. Identification of different depressive symptoms af-
ter mastectomy. Psychooncology. 2013;22(12):2857–2859.
36. Khan NF, Ward AM, Watson E, et al. Consulting and prescribing behaviour
for anxiety and depression in long-term survivors of cancer in the UK. Eur J
Cancer. 2010;46(18):3339–3344.
37. Otte JL, Carpenter JS, Russell KM, et al. Prevalence, severity, and correlates
of sleep-wake disturbances in long-term breast cancer survivors. J Pain
SymptomManage. 2010;39(3):535–547.
38. Rubino C, Figus A, Lorettu L, et al. Post-mastectomy reconstruction: a com-
parative analysis on psychosocial and psychopathological outcomes. J Plast
Reconstr Aesthet Surg. 2007;60(5):509–518.
39. Safarinejad MR, Shafiei N, Safarinejad S. Quality of life and sexual function-
ing in young women with early-stage breast cancer 1 year after lumpec-
tomy. Psychooncology. 2013;22(6):1242–1248.
40. Saleeba AK, Weitzner MA, Meyers CA. Subclinical psychological distress in
long-term survivors of breast cancer: a preliminary communication. J
Psychosoc Oncol. 1996;14(1):83–93.
41. Schairer C, Brown LM, Chen BE, et al. Suicide after breast cancer: an interna-
tional population-based study of 723,810 women. J Natl Cancer Inst. 2006;
98(19):1416–1419.
42. Suppli NP, Johansen C, Christensen J, et al. Increased risk for depression af-
ter breast cancer: a nationwide population-based cohort study of associated
factors in Denmark, 1998-2011. J Clin Oncol. 2014;32(34):3831–3839.
43. Weitzner MA, Meyers CA, Stuebing KK, et al. Relationship between quality
of life and mood in long-term survivors of breast cancer treated with mas-
tectomy. Support Care Cancer. 1997;5(3):241–248.
44. Yamada TH, Denburg NL, Beglinger LJ, et al. Neuropsychological outcomes
of older breast cancer survivors: cognitive features ten or more years after
chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22(1):48–54.
45. Aerts L, Christiaens MR, Enzlin P, et al. Sexual functioning in women after
mastectomy versus breast conserving therapy for early-stage breast cancer:
a prospective controlled study. Breast. 2014;23(5):629–636.
R
EV
IE
W
H. Carreira et al. | 15
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
46. Bailey EH, Perez M, Aft RL, et al. Impact of multiple caregiving roles on ele-
vated depressed mood in early-stage breast cancer patients and same-age
controls. Breast Cancer Res Treat. 2010;121(3):709–718.
47. Boehmer U, Ozonoff A, Timm A, et al. After breast cancer: sexual function-
ing of sexual minority survivors. J Sex Res. 2014;51(6):681–689.
48. Claus EB, Petruzella S, Carter D, et al. Quality of life for women diagnosed
with breast carcinoma in situ. J Clin Oncol. 2006;24(30):4875–4881.
49. Frazzetto P, Vacante M, Malaguarnera M, et al. Depression in older breast
cancer survivors. BMC Surg. 2012;12(suppl 1):S14.
50. Gurevich M, Devins GM, Wilson C, et al. Stress response syndromes in
women undergoing mammography: a comparison of women with and
without a history of breast cancer. PsychosomMed. 2004;66(1):104–112.
51. Hjerl K, Andersen EW, Keiding N, et al. Increased incidence of affective dis-
orders, anxiety disorders, and non-natural mortality in women after breast
cancer diagnosis: a nation-wide cohort study in Denmark. Acta Psychiatr
Scand. 2002;105(4):258–264.
52. Hung YP, Liu CJ, Tsai CF, et al. Incidence and risk of mood disorders in
patients with breast cancers in Taiwan: a nationwide population-based
study. Psychooncology. 2013;22(10):2227–2234.
53. Klein D, Mercier M, Abeilard E, et al. Long-term quality of life after breast
cancer: a French registry-based controlled study. Breast Cancer Res Treat.
2011;129(1):125–134.
54. Min SY, Kim HY, Jung SY, et al. Oncological safety and quality of life associ-
ated with mastectomy and immediate breast reconstruction with a latissi-
mus dorsi myocutaneous flap. Breast J. 2010;16(4):356–361.
55. Vazquez-Ortiz J, Antequera R, Picabia AB. Ajuste Sexual e imagen corporal
en mujeres mastectomizadas por cancer de mama. Psicooncologia. 2010;
7(2–3):433–451.
56. Von Ah D, Harvison KW, Monahan PO, et al. Cognitive function in breast
cancer survivors compared to healthy age- and education-matched women.
Clin Neuropsychol. 2009;23(4):661–674.
57. Von Ah DM, Russell KM, Carpenter J, et al. Health-related quality of life of af-
rican american breast cancer survivors compared with healthy African
American women. Cancer Nurs. 2012;35(5):337–346.
58. Yang H, Brand JS, Fang F, et al. Time-dependent risk of depression, anxiety,
and stress-related disorders in patients with invasive and in situ breast can-
cer. Int J Cancer. 2017;140(4):841–852.
59. Hermelink K, Buhner M, Sckopke P, et al. Chemotherapy and post-traumatic
stress in the causation of cognitive dysfunction in breast cancer patients. J
Natl Cancer Inst. 2017;109(10).
60. Bizetti PE, Ibde Jaquiel FJ, Madia Mantovani A, et al. Quality of life, depres-
sion and pain in women after breast cancer surgery. Ter Man. 2012;10(48):
161–167.
61. Lee MK, Park S, Lee ES, et al. Social support and depressive mood 1 year after
diagnosis of breast cancer compared with the general female population: a
prospective cohort study. Support Care Cancer. 2011;19(9):1379–1392.
62. Kim MS, Kim SY, Kim JH, et al. Depression in breast cancer patients who
have undergone mastectomy: a national cohort study. PLoS One. 2017;12(4):
e0175395.
63. El Rafihi-Ferreira R, Nogueira Pires ML, Zoega Soares MR. Sleep, quality of
life and depression in women in breast cancer post-treatment. Psicol Reflex
Crit. 2012;25(3):506–513.
64. Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a
cancer diagnosis. N Engl J Med. 2012;366(14):1310–1318.
65. Root JC, Andreotti C, Tsu L, et al. Learning and memory performance in
breast cancer survivors 2 to 6 years post-treatment: the role of encoding ver-
sus forgetting. J Cancer Surviv. 2016;10(3):593–599.
66. Myers JS, Wick JA, Klemp J. Potential factors associated with perceived cog-
nitive impairment in breast cancer survivors. Support Care Cancer. 2015;
23(11):3219–3228.
67. Collins B, Mackenzie J, Tasca GA, et al. Persistent cognitive changes in breast
cancer patients 1 year following completion of chemotherapy. J Int
Neuropsychol Soc. 2014;20(04):370–379.
68. Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and
cognitive function in women after adjuvant chemotherapy for breast can-
cer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol.
2005;23(31):8025–8032.
69. Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after
chemotherapy: a prospective longitudinal study in breast cancer patients. J
Natl Cancer Inst. 2006;98(23):1742–1745.
70. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast can-
cer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):
2695–2701.
71. Koppelmans V, Breteler MM, Boogerd W, et al. Neuropsychological perfor-
mance in survivors of breast cancer more than 20 years after adjuvant che-
motherapy. J Clin Oncol. 2012;30(10):1080–1086.
72. Kreukels BP, van Dam FS, Ridderinkhof KR, et al. Persistent neurocognitive
problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer.
2008;8(1):80–87.
73. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebel-
lar, and basal ganglia activity in adjuvant-treated breast cancer survivors
5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):
303–311.
74. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast
cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin
Exp Neuropsychol. 2004;26(7):955–969.
75. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the
effects of adjuvant treatments on cognition in women with early stage
breast cancer. Br J Cancer. 2006;94(6):828–834.
76. Voigt V, Neufeld F, Kaste J, et al. Clinically assessed posttraumatic stress in
patients with breast cancer during the first year after diagnosis in the pro-
spective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;
26(1):74–80.
77. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cogni-
tive changes associated with adjuvant treatment for breast cancer: impact
of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–4440.
78. McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated
with systemic chemotherapy for breast cancer: a prospective MRI study.
Breast Cancer Res Treat. 2010;123(3):819–828.
79. Miao H, Li J, Hu S, et al. Long-term cognitive impairment of breast cancer
patients after chemotherapy: a functional MRI study. Eur J Radiol. 2016;85(6):
1053–1057.
80. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume
and verbal memory performance associated with interleukin-6 and tumor
necrosis factor-alpha levels in chemotherapy-treated breast cancer survi-
vors. Brain Behav Immun. 2013;30:S109–S116.
81. Phillips KM, Jim HS, Small BJ, et al. Cognitive functioning after cancer treat-
ment: a 3-year longitudinal comparison of breast cancer survivors treated
with chemotherapy or radiation and noncancer controls. Cancer. 2012;
118(7):1925–1932.
82. Lejbak L, Vrbancic M, Crossley M. Endocrine therapy is associated with low
performance on some estrogen-sensitive cognitive tasks in postmeno-
pausal women with breast cancer. J Clin Exp Neuropsychol. 2010;32(8):
836–846.
83. Conroy SK, McDonald BC, Smith DJ, et al. Alterations in brain structure and
function in breast cancer survivors: effect of post-chemotherapy interval
and relation to oxidative DNA damage. Breast Cancer Res Treat. 2013;137(2):
493–502.
84. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of
brain gray and white matter demonstrated in breast cancer survivors ex-
posed to adjuvant chemotherapy. Cancer. 2007;109(1):146–156.
85. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on
brain metabolism in elderly women. J Natl Cancer Inst. 2002;94(8):592–597.
86. Nguyen CM, Yamada TH, Beglinger LJ, et al. Cognitive features 10 or more
years after successful breast cancer survival: comparisons across types of
cancer interventions. Psychooncology. 2013;22(4):862–868.
87. Angel K. The history of ‘Female Sexual Dysfunction’ as a mental disorder in
the 20th century. Curr Opin Psychiatry. 2010;23(6):536–541.
88. Pearce N. Analysis of matched case-control studies. BMJ. 2016;352:i969.
89. British Medical Association, Royal Pharmaceutical Society of Great Britain.
British National Formulary. 74th ed. London, UK; 2018.
90. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot
flushes in women with a history of breast cancer. Cochrane Database Syst
Rev. 2010; doi:10.1002/14651858.CD004923.pub2.
91. Lindsted KD, Fraser GE, Steinkohl M, et al. Healthy volunteer effect in a co-
hort study: temporal resolution in the Adventist Health Study. J Clin
Epidemiol. 1996;49(7):783–790.
92. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: les-
sons from history and study design issues. Semin Oncol. 2010;37(3):202–215.
93. Alexander S, Palmer C, Stone PC. Evaluation of screening instruments for
depression and anxiety in breast cancer survivors. Breast Cancer Res Treat.
2010;122(2):573–578.
94. Heo J, Chun M, Oh YT, et al. Psychiatric comorbidities among breast cancer
survivors in South Korea: a nationwide population-based study. Breast
Cancer Res Treat. 2017;162(1):151–158.
95. Lindberg P, Koller M, Steinger B, et al. Breast cancer survivors’ recollection of
their illness and therapy seven years after enrolment into a randomised
controlled clinical trial. BMC Cancer. 2015;15(1):554.
96. Saboonchi F, Petersson LM, Wennman-Larsen A, et al. Trajectories of anxi-
ety among women with breast cancer: a proxy for adjustment from acute to
transitional survivorship. J Psychosoc Oncol. 2015;33(6):603–619.
97. Swartzman S, Booth JN, Munro A, et al. Posttraumatic stress disorder after
cancer diagnosis in adults: a meta-analysis. Depress Anxiety. 2017;34(4):
327–339.
98. Cheng KKF, Wong WH, Koh C. Unmet needs mediate the relationship be-
tween symptoms and quality of life in breast cancer survivors. Support Care
Cancer. 2016;24(5):2025–2033.
99. Ellegaard MB, Grau C, Zachariae R, et al. Fear of cancer recurrence and
unmet needs among breast cancer survivors in the first five years. A cross-
sectional study. Acta Oncol. 2017;56(2):314–320.
100. Fiszer C, Dolbeault S, Sultan S, et al. Prevalence, intensity, and predictors of
the supportive care needs of women diagnosed with breast cancer: a sys-
tematic review. Psychooncology. 2014;23(4):361–374.
101. Khan NF, Evans J, Rose PW. A qualitative study of unmet needs and inter-
actions with primary care among cancer survivors. Br J Cancer. 2011;
105(suppl 1):S46–S51.
R
EV
IEW
16 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
102. Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical
aspects. Br J Psychiatry. 1974;125(0):355–373.
103. Diekstra RF. The epidemiology of suicide and parasuicide. Acta Psychiatr
Scand Suppl. 1993;371:9–20.
104. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced
cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.
105. Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task
Force recommendations to harmonise studies of cognitive function in
patients with cancer. Lancet Oncol. 2011;12(7):703–708.
106. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog—
methodological inconsistencies in the investigation of cognitive impair-
ment after chemotherapy. Breast Cancer Res Treat. 2006;95(2):125–129.
107. Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determi-
nants in breast cancer survivors. Breast J. 2005;11(6):440–447.
108. Hummel SB, Hahn DEE, van Lankveld J, et al. Factors associated with specific
diagnostic and statistical manual of mental disorders, fourth edition sexual
dysfunctions in breast cancer survivors: a study of patients and their part-
ners. J Sex Med. 2017;14(10):1248–1259.
109. Greendale GA, Petersen L, Zibecchi L, et al. Factors related to sexual function
in postmenopausal women with a history of breast cancer. Menopause. 2001;
8(2):111–119.
110. Ussher JM, Perz J, Gilbert E. Perceived causes and consequences of sexual
changes after cancer for women and men: a mixed method study. BMC
Cancer. 2015;15:268.
111. Helms RL, O’Hea EL, Corso M. Body image issues in women with breast can-
cer. Psychol Health Med. 2008;13(3):313–325.
112. Fobair P, Stewart SL, Chang S, et al. Body image and sexual problems in
young women with breast cancer. Psychooncology. 2006;15(7):579–594.
113. Oberguggenberger A, Martini C, Huber N, et al. Self-reported sexual health:
breast cancer survivors compared to women from the general population—
an observational study. BMC Cancer. 2017;17(1):599.
114. Bober SL, Giobbie-Hurder A, Emmons KM, et al. Psychosexual functioning
and body image following a diagnosis of ductal carcinoma in situ. J Sex Med.
2013;10(2):370–377.
115. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term
cancer survivors compared with spouses and healthy controls: a systematic
review and meta-analysis. Lancet Oncol. 2013;14(8):721–732.
116. Zainal NZ, Nik-Jaafar NR, Baharudin A, et al. Prevalence of depression in
breast cancer survivors: a systematic review of observational studies. Asian
Pac J Cancer Prev. 2013;14(4):2649–2656.
117. Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer
patients: a meta-analysis of diagnostic interviews and self-report instru-
ments. Psychooncology. 2014;23(2):121–130.
118. Walker J, Holm Hansen C, Martin P, et al. Prevalence of depression in adults
with cancer: a systematic review. Ann Oncol. 2013;24(4):895–900.
119. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in
breast cancer survivors previously treated with standard-dose chemother-
apy. J Clin Oncol. 2012;30(29):3578–3587.
120. Stover AM, Mayer DK, Muss H, et al. Quality of life changes during the pre-
to postdiagnosis period and treatment-related recovery time in older
women with breast cancer. Cancer. 2014;120(12):1881–1889.
121. Neuner JM, Zokoe N, McGinley EL, et al. Quality of life among a population-
based cohort of older patients with breast cancer. Breast. 2014;23(5):609–616.
122. Koch L, Jansen L, Herrmann A, et al. Quality of life in long-term breast can-
cer survivors—a 10-year longitudinal population-based study. Acta Oncol.
2013;52(6):1119–1128.
123. Brix SA, Bidstrup PE, Christensen J, et al. Post-traumatic growth among el-
derly women with breast cancer compared to breast cancer-free women.
Acta Oncol. 2013;52(2):345–354.
124. Petrie KJ, Buick DL, Weinman J, et al. Positive effects of illness reported by
myocardial infarction and breast cancer patients. J Psychosom Res. 1999;
47(6):537–543.
125. Morrill EF, Brewer NT, O’Neill SC, et al. The interaction of post-traumatic
growth and post-traumatic stress symptoms in predicting depressive
symptoms and quality of life. Psychooncology. 2008;17(9):948–953.
126. Syrowatka A, Motulsky A, Kurteva S, et al. Predictors of distress in female
breast cancer survivors: a systematic review. Breast Cancer Res Treat. 2017;
165(2):229–245.
127. Moschetti I, Cinquini M, Lambertini M, et al. Follow-up strategies for women
treated for early breast cancer. Cochrane Database Syst Rev. 2016; doi:
10.1002/14651858.CD001768.pub3.
128. Sulaica E, Han T, Wang W, et al. Vaginal estrogen products in hormone
receptor-positive breast cancer patients on aromatase inhibitor therapy.
Breast Cancer Res Treat. 2016;157(2):203–210.
129. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/
American Society of Clinical Oncology Breast Cancer Survivorship Care
Guideline. J Clin Oncol. 2016;34(6):611–635.
130. Costa AR, Fontes F, Pereira S, et al. Impact of breast cancer treatments on
sleep disturbances—a systematic review. Breast. 2014;23(6):697–709.
131. Turner R, Elson E. Sleep disorders. Steroids cause sleep disturbance. BMJ.
1993;306(6890):1477–1478.
132. Savard J, Davidson JR, Ivers H, et al. The association between nocturnal hot
flashes and sleep in breast cancer survivors. J Pain Symptom Manage. 2004;
27(6):513–522.
R
EV
IE
W
H. Carreira et al. | 17
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djy177/5164282 by London School of H
ygiene & Tropical M
edicine user on 15 N
ovem
ber 2018
